Amylin analogue peptide Cagrilintide for weight loss use

Cagrilintide is a novel glucagon-like peptide-1 (GLP-1) receptor agonist and analogues of glucagon-associated peptide-1 (amylin) for weight loss and the treatment of metabolic diseases. It is a drug developed by Novo Nordisk and is in clinical studies, particularly for use in combination with semaglutide to enhance weight loss.

Basic information about Cagrilintide:

Drug category: amylin (amylin) analogs.

Mechanism of action:

Amylin analogues: Cagrilintide mimics the effects of amylin to help regulate food intake and stomach emptying.

Promotes satiety: It enhances satiety by affecting the appetite regulation center in the brain, delaying stomach emptying, and reducing food intake.

For weight management: Cagrilintide is primarily used to treat obesity and related metabolic diseases, especially when combined with other weight loss drugs such as semaglutide.

Combination therapy:

Cagrilintide is often used in conjunction with semaglutide to improve weight management. Studies have shown that this combination can be more effective in promoting weight loss, especially in patients who have difficulty controlling their weight.

How does Cagrilintide help users lose weight?

The way Cagrilintide helps with weight loss is through the following mechanisms:

Increased satiety: Cagrilintide is an amylin analogue that slows stomach emptying by mimicking the effects of amylin, making people feel fuller longer after eating. This mechanism, which delays the expulsion of food from the stomach, reduces the frequency and amount of food eaten.

Regulating appetite centers: Cagrilintide helps reduce caloric intake by acting on appetite control centers in the brain, suppressing hunger. It reduces the urge to overeat and allows the individual to feel satisfied even when eating normally.

Synergies with GLP-1 drugs: Cagrilintide is often used in combination with GLP-1 receptor agonists, such as Semaglutide. GLP-1 drugs help with weight loss by regulating insulin secretion and blood sugar levels, while Cagrilintide enhances feelings of fullness. The combined effect of the two significantly improved weight loss.

Slow stomach emptying: Cagrilintide further reduces the need to eat by slowing down the digestion process of food and reducing the release of hunger hormones.

These mechanisms work together to help users reduce their daily calorie intake, which effectively promotes weight loss.

What makes Cagrilintide unique compared to other drugs?

Cagrilintide is unique in the mechanism of action of its amylin analogues. The role of amylin in weight regulation has been overlooked for many years, and the emergence of Cagrilintide fills this gap by delaying gastric emptying and enhancing satiety, which is different from the mechanism of action of traditional GLP-1 agonists (such as Semaglutide), resulting in more significant weight loss.

Multiple layers of weight regulation:

Because Cagrilintide works by mimicking amylin, which affects multiple mechanisms related to hunger, digestion, and metabolism, it may have the potential for more long-term effects, not only effective in weight loss, but also to help improve metabolic health.

Non-irritating:

Unlike some weight loss medications that promote metabolism or act through the nervous system, such as amphetamine-type medications, Cagrilintide does not stimulate the nervous system and therefore does not usually trigger common side effects such as insomnia, anxiety, or heart palpitations.

When Cagrilintide is used in combination with GLP-1 receptor agonists, such as Semaglutide, the combination is able to work synergistically to promote weight loss through different mechanisms. GLP-1 agonists help reduce appetite by regulating insulin secretion and blood sugar levels, while Cagrilintide further improves weight loss by enhancing feelings of fullness and delaying gastric emptying.

Stronger combination: The combination of Cagrilintide and GLP-1 was shown to significantly increase weight loss compared with GLP-1 alone, especially in patients who did not respond well to the single drug.

Top of form

How is Cagrilintide used?

Cagrilintide is administered primarily by injection, usually as part of a long-term weight management program. It is administered in a similar way to other weight loss drugs (such as Semaglutide), with the frequency and dosage of injections gradually determined based on the results of clinical studies. Here are the key points to use Cagrilintide:

Injection route:

Cagrilintide is administered by subcutaneous injection, similar to how insulin or GLP-1 drugs are used. The injection site is usually chosen in the subcutaneous adipose tissue area of the abdomen, thigh or upper arm.

Frequency of administration:

Once a week: Cagrilintide is currently used in clinical trials as an injection once a week. This frequency of administration is similar to GLP-1 drugs such as Semaglutide, facilitating long-term use and patient compliance.

In combination with Semaglutide:

In some treatment options, Cagrilintide is used in combination with Semaglutide, usually both are injected together. The purpose of this combination is to achieve more significant weight loss through two different mechanisms of action.

The combination of Cagrilintide and Semaglutide injected weekly has shown significant effects in reducing appetite and promoting weight loss.

Gradually increase the dose:

Similar to many weight loss drugs, Cagrilintide may be administered at a lower dose and gradually increased to reduce side effects and allow the body to gradually adjust to the drug. This incremental strategy helps reduce side effects such as nausea, vomiting, or gastrointestinal upset that may occur initially.

Preparation before use:

Before injection, the medication is usually provided in the form of a pre-loaded injection pen or small syringe, which is relatively simple to use. The patient only needs to follow the doctor's advice or guidance to inject and ensure that the injection site is clean.

Before patients can start using Cagrilintide, they usually need professional medical training to understand injection techniques, dosage adjustments, and how to deal with potential side effects.

Monitoring in combination therapy:

If Cagrilintide is used in combination with Semaglutide or another drug, patients typically need to be monitored regularly to evaluate the drug's effectiveness and safety. This may include an assessment of weight, blood sugar, cardiovascular health and more.

Coping with common side effects:

Common side effects may include nausea, vomiting, flatulence, and stomach upset. Patients should closely monitor their body's reaction and contact their doctor to adjust the dose or frequency of injections if necessary.

In SUMMARY:

Cagrilintide is administered as a weekly subcutaneous injection, often in combination with Semaglutide to enhance weight loss. Drug doses usually start at a low dose and are gradually increased to reduce side effects and help patients adapt.